This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
PA Boyer , P Skolnick , LH Fossom (1998). Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain: a quantitative in situ hybridization study. Journal of Molecular Neuroscience 10, 219–233.
GE Crane (1959). Cycloserine as an anti-depressant agent. American Journal of Psychiatry 115, 1025–1029.
GE Crane (1961). The psychotropic effects of cycloserine: a new use for an antibiotic. Comprehensive Psychiatry 2, 51–59.
AR Entsuah , H Huang , ME Thase (2001). Response and remission rates in different sub-populations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. Journal of Clinical Psychiatry 62, 869–877.
E Frank , RF Prien , RB Jarrett , MB Keller (1991). Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse and recurrence. Archives of General Psychiatry 48, 851–855.
M Hamilton (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23, 56–62.
U Heresco-Levy , DC Javitt , Y Gelfin , E Gorelik , (2006). Controlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. Journal of Affective Disorders 93, 239–243.
Y Ji , S Hebbring , H Zhu , GD Jenkins (2011). Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clinical Pharmacology and Therapeutics 89, 97–104.
G Neeman , M Blanaru , B Bloch , I Kremer , (2005). Relation of plasma glycine, serine and homocysteine levels to schizophrenia symptoms and medication type. American Journal of Psychiatry 162, 1738–1740.
MM Norberg , JH Krystal , DF Tolin (2008). A meta-analysis of d-cycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry 63, 1118–1126.
SH Preskorn , B Baker , S Kolluri , FS Menniti , (2008). An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selection N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Journal of Clinical Psychopharmacology 28, 631–637.
G Sanacora , R Gueorguieva , CN Epperson , YT Wu , (2004). Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Archives of General Psychiatry 61, 705–713.
G Sanacora , CA Zarate , JH Krystal , HK Manji (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 7, 426–437.
M Shleper , E Kartvelishvily , H Wolosker (2005). D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices. Journal of Neuroscience 25, 9413–9417.
P Skolnick , P Popik , R Trullas (2009). Glutamate-based antidepressants: 20 years on. Trends in Pharmacological Sciences 30, 563–569.
T Sumiyoshi , AE Anil , D Jin , K Jayathilake , (2004). Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. International Journal of Neuropsychopharmacology 7, 1–8.
ME Thase , BR Haight , N Richard , CB Rockett , (2005). Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. Journal of Clinical Psychiatry 66, 974–981.
BN van Berckel , C Lipsch , C Gispen-de Wied , HJ Wynne , (1998). The partial NMDA agonist d-cycloserine stimulates LH secretion in healthy volunteers. Psychopharmacology (Berlin) 138, 190–197.
BN van Berckel , C Lipsch , S Timp , C Gispen-de Wied , (1997). Behavioral and neuroendocrine effects of the partial NMDA agonist d-cycloserine in healthy subjects. Neuropsychopharmacology 16, 317–324.